Previous trials have demonstrated the effects of fluvoxamine alone and inhaled budesonide alone for prevention of disease progression among outpatients with COVID-19.
Purpose Life SciencesMay 23, 2023
Purpose Life Sciences, a global impact research organization, today announced the appointment of Bob Battista as EVP, Chief Strategy & Commercial Officer. In this role, Bob is responsible for building the company’s strategic direction and commercial activities, including deep market innovation initiatives with its clients and partners.
Purpose Life SciencesMay 23, 2023
Intramuscular injection of long-acting cabotegravir and rilpivirine is a novel, long-acting antiretroviral therapy (ART) combination approved for use as a fully suppressive regimen for people living with HIV.
rmazziMay 2, 2023
With billions of dollars in research and development funding continuing to be invested, COVID-19 has become into a singular focus for the scientific community. However, the collective response from the scientific communities has seen poor return on investment, particularly for therapeutic research for COVID-19, revealing the existing weaknesses and inefficiencies…
rmazziMay 14, 2021
The COVID-19 pandemic has put enormous pressure on the medical research community to move quickly, yet many clinical trials have been arguably inefficient with questionable methdological quality. The pandemic has highlighted the need for more collaboration and coordination, with large scale clinical trials and master protocols that can inform policy…
Purpose Life SciencesMay 1, 2021
